- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Pharmaceutical
Biopharma fueling boom in refrigerated warehousing
May 29, 2010
Chris O'MalleyIn the past few years, a handful of cold storage facilities have sprouted locally by playing to Indianapolis' strengths
in warehousing and life sciences.
MoreEffective stats are new hurdle for U.S. drugmakers
May 26, 2010
J.K. WallWellPoint Inc.'s announcement of comparative effectiveness research guidelines last week marks a new era for U.S. drugmakers.
The Indianapolis-based health insurer will use studies that compare the effectiveness of one drug against another as a complement
to typical clinical trial research that compares a drug against a placebo sugar pill.
MoreDrug-spending increase highest in four years
May 20, 2010
Bloomberg NewsThe price increase was fueled by the debate over the health-care overhaul in Washington, D.C., Medco Health Solutions Inc.
CEO David Snow said.
MoreLilly hopes Elanco unit becomes a cash cow
May 8, 2010
J.K. WallElanco Animal Health chief Jeff Simmons predicts that consumers will opt for food made cheaper by using
Elanco's productivity-enhancing drugs over pricier organic and locally grown products. But, as a hedge,
he has Elanco developing products to help organic farmers, too.
MoreLatest Lilly job cuts target marketing employees
May 7, 2010
J.K. WallIndianapolis-based drugmaker Eli Lilly and Co. is on course to cut 5,500 jobs by the end of 2011 in a bid to eliminate $1
billion in annual expenses.
MoreLilly sues to block copy of Evista osteoporosis drug
May 5, 2010
Bloomberg NewsWatson Pharmaceuticals filed for FDA approval to sell a low-cost version of Eli Lilly and Co.'s osteoporosis medicine. Indianapolis-based
Lilly is seeking a court order that would block approval until three of its patents expire in 2017.
MoreClosing of Purdue's Chao Center is setback for BioCrossroads
May 1, 2010
J.K. WallThe university is hoping to find a private company to take over the 5-year-old facility, which formulated and manufactured
small batches of drugs used in clinical trials.
MoreMedco Health profits climb as it adds big clients
April 28, 2010
IBJ Staff and Associated PressMedco, which operates a major pharmacy and distribution center in Whitestown, got a boost from higher prices on brand-name
drugs and from greater sales of more profitable generic drugs.
MoreChao exit hurts drug development industry
April 28, 2010
J.K. WallPurdue University’s decision to close the Chao Center in West Lafayette is a setback for Indiana’s effort to grow
a vibrant contract drug manufacturing sector. But it’s just the latest in a series of unexpected changes—not all
for
the worse—since Indianapolis-based BioCrossroads launched a contract drug manufacturing initiative in late 2007.
MoreHarlan Labs names new CEO
April 23, 2010
IBJ StaffThe Indianapolis-based provider of clinical research animals has promoted senior manager Hans Thunem to its top spot.
MoreDrug prices rise ahead of rebates
April 21, 2010
J.K. WallDrug prices rose faster last year than they have in a decade—just in time for big rebates the drug industry promised
as part of the health reform law.
MoreLilly to pay $400M to repurchase Cymbalta rights
April 19, 2010
Bloomberg NewsEli Lilly and Co. will repurchase rights to develop and market antidepressant Cymbalta outside the U.S. and Japan from European
partner Boehringer Ingelheim for an initial payment of $400 million.
MoreLilly diabetes drug may have cancer risk, FDA says
April 9, 2010
IBJ Staff and Bloomberg NewsOnce-weekly form of Byetta is awaiting the FDA's OK. Analyst predict the new version of the drug, if approved, could rack
up sales of $2 billion annually.
MoreLouisiana gets $20M in Lilly drug settlement
April 7, 2010
Associated PressLouisiana was one of 13 states that filed individual suits in state courts over allegations that Lilly pushed Zyprexa for
uses that had not been approved by federal regulators.
MoreLilly wins court ban on generic copy of Gemzar
April 1, 2010
Bloomberg News, Associated PressEli Lilly and Co. won a U.S. court ruling Wednesday that bars Teva Pharmaceutical Industries Ltd. from selling a generic version
of the cancer drug Gemzar until November.
MoreLilly drug wins U.K. backing as cancer therapy
April 1, 2010
Bloomberg NewsEli Lilly and Co.'s Alimta has received the preliminary backing of a United Kingdom agency as a maintenance treatment for
patients with the most common form of lung cancer.
MoreLilly to let 115 workers go in new outsourcing deal
March 26, 2010
J.K. WallDeal with unit of Massachusetts-based Thermo Fisher Scientific would keep many of the employees working in same
location.
MoreLilly sues Hospira over generic version of Gemzar
March 24, 2010
Bloomberg NewsIndianapolis-based Eli Lilly and Co. sued rival drugmaker Hospira Inc. to prevent it from selling a generic version of the
cancer drug Gemzar before a patent on the medicine expires in 2013.
MoreAriad loses $65M patent appeal against Eli Lilly
March 22, 2010
Bloomberg NewsMonday's decision throws out a $65.2 million patent-infringement verdict won by Ariad for royalties on Lilly's osteoporosis
drug Evista and sepsis medicine Xigris.
MoreBill kicks off years of change for local health care players
March 22, 2010
J.K. WallSweeping changes phase in slowly for most, but insurers, hospitals, drug companies, employers, workers, medical device makers
and more will eventually feel impact.
MoreReform offers risk, opportunities for Lilly, WellPoint
March 22, 2010
IBJ Staff and Bloomberg NewsDrugmakers and insurers could gain millions of customers under the legislation, but the industry also will pay new fees and
face stricter rules that may shrink profit and fuel mergers.
MoreLilly sues to block generic of Adcirca lung treatment
March 17, 2010
Bloomberg NewsNetherlands-based Synthon Pharmaceuticals is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine.
MoreLilly victim of theft from Connecticut warehouse
March 16, 2010
IBJ Staff and Associated PressPharmaceuticals stolen Sunday morning could be worth up to $75 million.
MoreLilly pays $50M-plus for rights to testosterone lotion
March 16, 2010
Bloomberg NewsIndianapolis-based Lilly will pay Acrux of West Melbourne, Australia, a $50 million license fee, plus $3 million when manufacturing
assets are transferred, but the deal could be worth millions more.
MoreFDA says 'not yet' on Lilly's once-weekly Byetta
March 15, 2010
J.K. WallRegulators won't require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling,
manufacturing
processes.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Laura-the festivals and tastings are free. What does is strengthen the sense of community with activities. What are those empty lots doing for the Village? it's sad you can't see the good that this progress can do for the area. No one is requiring anyone to shop there. I guess you'd rather see a Dollar store move in or no, we'd rather see the property stand empty b/c change is out of the question.
Read down to the part about Brizzi. Someone needs to subpoena his "purchases" of Red RockPictures and Cellstar and his corresponding bank records, I mean c'mon, I'd like to see his alcohol usage records, too. http://diana-vice.blogspot.com/2011_01_01_archive.html
Wonder if my neighborhood can advertise our "retention" pond and act like it is a beach too?
a new record at the '11 salebration until they realized that it was a futile effort to get their crapwagon moter and crapwagon car up speed. And then they just quietly slunk off into the night and never spoke of it again. Nothing to see here folks.
millions for putting a company's bumper sticker on one of its Lolas. But you gotta take what you can get.